The long-term goal of this work is to rationally manipulate G protein-coupled receptor (GPCRs) activation with the hope to develop novel therapeutic approaches in this major family of transmembrane receptors and drug targets. Our hypothesis is that different GPCRs share common elements of their signal transduction mechanism. If so, it should be possible to compare and contrast their sequences to reveal functionally relevant amino acid variation patterns, some that are common to all receptors and indicative of shared mechanisms, and others that are unique to some branches of the family and indicative of ligand-specific mechanisms. This principle led to a general algorithm, called the Evolutionary Trace (ET) that correlates residue substitutions with evolutionary divergences and thus ranks the evolutionary importance of a protein's residues. It was shown, in the past funding period that ET could search protein structure for functional sites and their specificity determinants on a large-scale. Mutations guided to ET's top-ranked residues (so-called "trace residues") repeatedly blocked, separated, mimicked, or rewired protein interactions in numerous experimental case studies in GPCRs and in other proteins. In parallel, high-throughput ET analyses suggested that trace residues have distinctive and quantifiable and proteome-wide properties in terms of structural clustering, biophysical interaction, and functional specificity. This proposal builds on these observations by pursuing three specific aims: 1. To redirect ligand binding in bioamine receptors. 2. To redesign ligand binding and dimerization in metabotropic glutamate receptors. 3. To identify transmembrane GPCR response modulators on a large scale. The outcome should reveal new aspects of the molecular basis of signaling in an important family of pharmaceutical targets. It will also link sequence and structure genomics databases to the molecular basis of function and to the rational re-design of protein interactions - key steps towards manipulating cellular pathways. It will benefit human health by providing new approaches to rational drug design and by enhancing the diagnostic value of SNP analysis and human genotyping.

Public Health Relevance

The few G protein coupled receptors that have been successfully targeted by drugs so far still provide the basis for nearly half of all current medications. The difficulty in creating medications against them is that we have limited knowledge of how they work. This proposal attempts to uncover the mechanisms of these proteins so that we can design new drugs that block their role in diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
3R01GM066099-09S1
Application #
8734287
Study Section
Special Emphasis Panel (ZRG1-BCMB-B (02))
Program Officer
Dunsmore, Sarah
Project Start
2002-07-01
Project End
2014-08-31
Budget Start
2011-09-01
Budget End
2014-08-31
Support Year
9
Fiscal Year
2013
Total Cost
$149,638
Indirect Cost
$54,023
Name
Baylor College of Medicine
Department
Genetics
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Wilson, Stephen J; Wilkins, Angela D; Lin, Chih-Hsu et al. (2016) DISCOVERY OF FUNCTIONAL AND DISEASE PATHWAYS BY COMMUNITY DETECTION IN PROTEIN-PROTEIN INTERACTION NETWORKS. Pac Symp Biocomput 22:336-347
Sung, Yun-Min; Wilkins, Angela D; Rodriguez, Gustavo J et al. (2016) Intramolecular allosteric communication in dopamine D2 receptor revealed by evolutionary amino acid covariation. Proc Natl Acad Sci U S A 113:3539-44
Marciano, David C; Lua, Rhonald C; Herman, Christophe et al. (2016) Cooperativity of Negative Autoregulation Confers Increased Mutational Robustness. Phys Rev Lett 116:258104
Koire, Amanda; Katsonis, Panagiotis; Lichtarge, Olivier (2016) REPURPOSING GERMLINE EXOMES OF THE CANCER GENOME ATLAS DEMANDS A CAUTIOUS APPROACH AND SAMPLE-SPECIFIC VARIANT FILTERING. Pac Symp Biocomput 21:207-18
Gallion, Jonathan; Wilkins, Angela D; Lichtarge, Olivier (2016) HUMAN KINASES DISPLAY MUTATIONAL HOTSPOTS AT COGNATE POSITIONS WITHIN CANCER. Pac Symp Biocomput 22:414-425
Lua, Rhonald C; Wilson, Stephen J; Konecki, Daniel M et al. (2016) UET: a database of evolutionarily-predicted functional determinants of protein sequences that cluster as functional sites in protein structures. Nucleic Acids Res 44:D308-12
Mullany, Lisa K; Wong, Kwong-Kwok; Marciano, David C et al. (2015) Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival. Neoplasia 17:789-803
Peterson, Sean M; Pack, Thomas F; Wilkins, Angela D et al. (2015) Elucidation of G-protein and β-arrestin functional selectivity at the dopamine D2 receptor. Proc Natl Acad Sci U S A 112:7097-102
Neskey, David M; Osman, Abdullah A; Ow, Thomas J et al. (2015) Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. Cancer Res 75:1527-36
Osman, Abdullah A; Monroe, Marcus M; Ortega Alves, Marcus V et al. (2015) Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. Mol Cancer Ther 14:608-19

Showing the most recent 10 out of 72 publications